Proving the Business Case for the Internet of Things

WellSpan picks Sweetch AI app for personal diabetes management

William Payne
November 1, 2018

Diabetes smart tech specialist Sweetch is partnering with Maryland and Pennsylvania healthcare provider WellSpan Health.  The partnership's first phase will provide Sweetch's mobile health app to WellSpan Health's 15,000 employees, including 200 primary care and specialty physicians and advanced practice clinicians in central Pennsylvania and northern Maryland.

Israeli company Sweetch has developed an AI digital therapeutics solution to help predict, prevent and improve outcomes among people with diabetes.

"This is the tool we have been looking for to augment our wellness assessment programme," said Charles Chodroff, MD, WellSpan Health's Senior Vice President, Population Health and Chief Clinical Officer. "We have been leaders in developing effective wellness programmes for our employees and the local business community for many years and have been providing detailed personalised assessments identifying chronic disease risk factors. This new smartphone platform will take our programme to the next level, by helping to target those individuals who are at the greatest risk by giving them a super-personalised tool, which automatically adapts to each individual's life habits."

The Centers for Disease Control and Prevention (CDC) estimates 33.9% of US adults aged 18 years or older have pre-diabetes. Medical expenditures of people with diabetes are approximately 2.3 times higher than expected costs if they did not have diabetes. Effective interventions that prevent or delay type 2 diabetes and diabetic complications result in substantial long-term savings in healthcare costs.

Using its proprietary machine learning algorithm, Sweetch quantifies personal diabetes risk to help enable early and effective prevention. 

For personal health management, Sweetch's mobile health app with its connected bluetooth digital scale monitors and analyses the user's personal, environmental and behavioural digital bio-markers. This results in contextual, real-time specific and detailed recommendations that guide the user towards achieving disease prevention goals. This could include advising the user to take a five-minute walk to a nearby coffee shop in the middle of the day based on his calendar availability, to achieve their 20-minute activity goal. By applying predictive analytics, Sweetch continuously optimises the user's goals and messages, in order to predict which of these messages will trigger action with an emphasis on long-term engagement.

"We are very excited to work with the WellSpan Health team," said Dana Chanan, CEO and Co-Founder of Sweetch. "Diabetes is one of the world's most common and costly chronic illnesses, affecting one in 11 adults globally. AI and machine learning is a must-have for fighting this epidemic. We see a great opportunity to collaborate with a leading healthcare organisation that has its mission to improve health through exceptional care for all, lifelong wellness and healthy communities."

In a recently published clinical trial conducted by Johns Hopkins, Sweetch demonstrated clinically significant effects on weight reduction, physical activity increase, and Haemoglobin A1C reduction. The Sweetch solution offered through WellSpan Health is composed of a mobile app and wireless Bluetooth-connected scale.